KalVista Pharmaceuticals, Inc. $KALV Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 54.6% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 21,828 shares of the specialty pharmaceutical company’s stock after selling 26,202 shares during the quarter. SG Americas Securities LLC’s holdings in KalVista Pharmaceuticals were worth $439,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company increased its stake in shares of KalVista Pharmaceuticals by 5.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock worth $165,000 after acquiring an additional 818 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the period. Rhumbline Advisers increased its position in KalVista Pharmaceuticals by 2.8% during the second quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after purchasing an additional 1,458 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in KalVista Pharmaceuticals by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 324,369 shares of the specialty pharmaceutical company’s stock worth $5,239,000 after purchasing an additional 2,402 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in KalVista Pharmaceuticals by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock worth $281,000 after purchasing an additional 2,939 shares during the last quarter.

Insider Activity at KalVista Pharmaceuticals

In related news, CFO Brian Piekos sold 1,862 shares of the stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total transaction of $37,649.64. Following the completion of the transaction, the chief financial officer owned 18,150 shares of the company’s stock, valued at approximately $366,993. This trade represents a 9.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Paul K. Audhya sold 2,686 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $54,310.92. Following the completion of the sale, the insider directly owned 142,547 shares in the company, valued at approximately $2,882,300.34. The trade was a 1.85% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 39,971 shares of company stock valued at $965,493. 4.30% of the stock is owned by insiders.

KalVista Pharmaceuticals Price Performance

Shares of KALV opened at $27.00 on Thursday. The company’s 50-day moving average price is $26.74 and its 200 day moving average price is $20.30. KalVista Pharmaceuticals, Inc. has a 12-month low of $9.83 and a 12-month high of $27.00. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. The firm has a market cap of $1.44 billion, a P/E ratio of -7.80 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $40.86 million for the quarter, compared to the consensus estimate of $39.03 million. On average, sell-side analysts forecast that KalVista Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. HC Wainwright lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $37.00 to $27.00 in a report on Friday, May 1st. Stifel Nicolaus lifted their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Leerink Partners lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Citizens Jmp cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Finally, JonesTrading lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Three investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, KalVista Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $33.25.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.